Go to the Indico Home Page Oldest event Older event Up to category Newer event Newest event
  • Indico style
  • Indico style - inline minutes
  • Indico style - numbered
  • Indico style - numbered + minutes
  • Indico Weeks View
    • Switch to the management area of this event
    Login

    EUROPEAN CONGRESS AND EXHIBITION ON ADVANCED MATERIALS AND PROCESSES - EUROMAT 2021

    13–17 Sept 2021 Virtual Conference
    Virtual
    Europe/Vienna timezone
    Thank you very much for your participation!

    Conference Secretary

    Microfluidic preparation of targeted nanoparticles for oral anti-diabetic peptide delivery

    17 Sept 2021, 17:40
    20m
    Room 15

    Room 15
    Oral Presentation F5. Synthetic polymer for medical applications (incl. F8) F5_Synthetic polymer for medical applications

    Speaker

    João Pedro Martins (Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki)

    Description

    The relative success of the currently used diabetes therapies depends on frequent and painful injections, with numerous associated complications and low patient compliance.[1] The oral administration of nanoparticles (NPs) loaded with anti-diabetic drug holds tremendous promise in this field.[2] In line with recent advances in targeted drug delivery,[3] we propose the development of neonatal Fc receptor (FcRn)-targeted NPs for oral administration of anti-diabetic peptides.
    Undecylenic acid modified thermally hydrocarbonized porous silicon (UnTHCPSi) NPs were loaded with glucagon peptide-1 (GLP-1) by an immersion method.[4] The NPs were functionalized with the Fc fragment of immunoglobulin G for targeting purposes,[5] coated with mucoadhesive chitosan, and entrapped into a pH-responsive polymeric matrix by glass-capillary microfluidics. The NPs were characterized for their physicochemical properties, pH-responsiveness and drug release. In vitro cytotoxicity, cell-NP interactions and drug permeability were also evaluated.
    We successfully produced GLP-1-loaded pH-sensitive FcRn-targeted nanoparticles. The formulation presented a monodisperse size distribution, pH-responsive properties and sustained drug release. High cytocompatibility, increased levels of interaction with the cells and enhanced drug absorption at the intestinal level were observed when the NPs were functionalized with the targeting ligands. Overall, these NPs offer a toolbox in the development of targeted therapies, paving the way for making for oral delivery of anti-diabetic drugs a reality.

    [1] P. Fonte, F. Araújo, C. Silva, C. Pereira, S. Reis, H.A. Santos, B. Sarmento, Biotechnology Advances 2015, 33 (6, Part 3), 1342-1354.
    [2] M.A. Eaton, L. Levy, O.M. Fontaine, Nanomedicine: NMB 2015, 11(4), 983-992.
    [3] F. Araújo, J.d. Neves, J.P. Martins, P.L. Granja, H.A. Santos, B. Sarmento, Progress in Materials Science 2017, 89, 306-344.
    [4] H. A. Santos, E. Mäkilä, A. J. Airaksinen, L. M. Bimbo, J. Hirvonen, Nanomedicine 2014, 9, 535.
    [5] J.P Martins, P.J. Kennedy, H. A. Santos, C. Barrias, B. Sarmento, Pharmachology & Therapeutics 2016, 161, 22-39.

    Speaker Country Finland

    Author

    João Pedro Martins (Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki)

    Co-authors

    Dongfei Liu (Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki FI-00014, Finland and Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki FI-00014, Finland) Flavia Fontana (Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki FI-00014, Finland) Mónica P. A. Ferreira (Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki FI-00014, Finland) Alexandra Correia (Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki FI-00014, Finland) Silvia Valentino (Department of Drug Sciences, Università degli Studi di Pavia, Viale Taramello 12, 27100 Pavia, Itália) Marianna Kemell (Department of Chemistry, University of Helsinki, Helsinki FI-00014, Finland) Karina Moslova (Department of Chemistry, University of Helsinki, Helsinki FI-00014, Finland) Ermei Mäkilä (Department of Physics and Astronomy, University of Turku, Turku FI-20014, Finland) Jarno Salonen (Department of Physics and Astronomy, University of Turku, Turku FI-20014, Finland) Jouni Hirvonen (Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki FI-00014, Finland) Bruno Sarmento (i3S - Instituto de Investigação e Inovação em Saúde/INEB - Instituto de Engenharia Biomédica, University of Porto, 4200-135 Porto, Portugal, and CESPUInstituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, 4585-116 Gandra, Portugal) Hélder A. Santos (Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki FI-00014, Finland and Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki FI-00014, Finland)

    Presentation materials

    There are no materials yet.